VEGF Inhibitors Do Not Increase D-dimer Levels in Colorectal Cancer Patients Without Venous Thromboembolism: A Retrospective Non-inferiority Analysis

In Vivo. 2019 Nov-Dec;33(6):2117-2123. doi: 10.21873/invivo.11712.

Abstract

Background/aim: If VEGF inhibitors contribute to an increase in D-dimer levels, they may adversely affect the diagnosis of venous thromboembolism (VTE). Consequently, this retrospective study examined the effects of VEGF inhibitors on D-dimer levels in colorectal cancer patients.

Patients and methods: A total of 104 colorectal cancer patients who received chemotherapy, were included in this study. To perform D-dimer analysis, patients were divided into two analysis targets: patients with VTE and without VTE. Statistical analysis included a natural logarithmic transformation of D-dimer data.

Results: In the D-dimer analysis of non-VTE patients, the natural logarithm D-dimer mean difference was -0.186, with a 95% CI of -0.525 to 0.154. The upper limit of the 95%CI (0.154) did not exceed the non-inferiority margin (Δ) of 0.199, and therefore met the non-inferiority criteria.

Conclusion: VEGF inhibitors don't contribute to increased D-dimer levels in colorectal cancer patients without VTE.

Keywords: Pan-Asian adapted ESMO consensus guidelines; Vascular endothelial growth factor inhibitor; chemotherapy; deep vein thrombosis; pulmonary embolism.

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / complications
  • Colorectal Neoplasms / diagnosis
  • Colorectal Neoplasms / drug therapy*
  • Female
  • Fibrin Fibrinogen Degradation Products* / metabolism
  • Humans
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Venous Thromboembolism / diagnosis
  • Venous Thromboembolism / etiology

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • Vascular Endothelial Growth Factor A
  • fibrin fragment D